<DOC>
	<DOCNO>NCT00501137</DOCNO>
	<brief_summary>Primary objective determine antibody responses HPV type 16 &amp; 18 non-inferior 2-dose paediatric regimen compare 3-dose adult regimen Q-HPV vaccination , response measure Month 7 .</brief_summary>
	<brief_title>A Controlled Trial Assess Immunogenicity Proposed Paediatric Dosing Schedule Human Papillomavirus Vaccine</brief_title>
	<detailed_description>Human Papillomavirus ( HPV ) infection cause cervical cancer . Immunogenicity , safety efficacy prevention persistent infection HPV 16 18 proven use 3-dose regimen adolescent adult female use Quadrivalent Human Papillomavirus ( Q-HPV ) vaccine . The intensity immune response inversely proportional age . Immunogenicity adolescents 9-15 year age 1.7 - 2 time great 16-26 year old vaccine recipient . Paediatric dose study necessary prudent give limited provincial funding new biologics acquisition programme service delivery . A reduction adult 3-dose HPV vaccine regimen pediatric 2-dose regimen result increase compliance full vaccine series significant saving health care system cost biologics program delivery administration .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A female , include , 913 year ( 14th birthday ) 1626 year age ( 27th birthday ) time first vaccination . Healthy Not pregnant Four le sexual partner lifetime report subject . ( Sexual activity define intercourse ) Not plan become pregnant likely become pregnant No report history genital warts No laboratory confirm history cervical intraepithelial neoplasia No previous vaccination HPV No administration immunoglobulin and/or blood product within three month precede first dose study vaccine plan administration study period No previous anaphylactic reaction HPV vaccine vaccine relate component include aluminum hydroxyphosphate sulfate polysorbate 80 No confirm suspect immunosuppressive immunodeficient condition base medical history No bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . Can already enrol clinical trial investigational vaccine drug administer Exclusion Criteria Pregnant Female plan become pregnant likely become pregnant ( determined investigator ) study duration Part 1 ( 07 month ) Reported history genital warts Laboratory confirm history cervical intraepithelial neoplasia Greater four lifetime sexual partner involve sexual intercourse Previous vaccination HPV Administration immunoglobulin and/or blood product within three month precede first dose study vaccine plan administration study period A previous anaphylactic reaction HPV vaccine vaccine relate component include aluminum hydroxyphosphate sulfate polysorbate 80 Any confirm suspected immunosuppressive immunodeficient condition base medical history ( e.g . HIV infection , genetic defect , immunosuppressive therapy ) . *Chronic administration ( defined 14 day ) immunemodifying drug within 6 month prior first vaccine dose plan use study period exclusionary ( corticosteroid use immunemodifying level â‰¥0.5 mg/kg/day ; inhaled topical steroid acceptable ) . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection ( thrombocytopaenia , coagulation disorder , anticoagulant therapy ) . Enrollment clinical trial investigational vaccine drug administer</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HPV</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Gardasil</keyword>
	<keyword>Human Papillomavirus</keyword>
	<keyword>vaccine</keyword>
	<keyword>2 dose versus 3</keyword>
</DOC>